Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2000

01-12-1999 | Paper Report

CD30 involvement in self tolerance of T cells

Author: Sarah Parry

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Excerpt

CD30 is a member of the tumour necrosis factor (TNF) receptor superfamily, and is expressed on activated T and B cells. Here, the authors investigate the role of CD30 in self-tolerance of autoreactive CD8+ T cells. An autoimmune diabetes model system was used where ovalbumin (ova)-specific CD8+ T cells from the OT-1 transgenic mouse line were adoptively transferred into unirradiated transgenic mice that expressed ova in the pancreatic beta cells and the proximal tubular cells of the kidney (RIP-mOVA mice). In this model, wild type OT-1 CD8+ T cells caused diabetes only when transferred in large numbers, with lower doses being effectively tolerised. Such tolerance is believed to be due to autoantigen from pancreatic cells moving to draining lymph nodes, where it causes activation and subsequent deletion of autoreactive T cells - termed cross-tolerance. This mechanism is dependent on Fas (CD95). The role of CD30 in the maintenance of tolerance was investigated by adoptively transferring CD30-deficient (CD30-/-) OT-1 cells into RIP-mOVA mice, and following the fate of these T cells. …
Literature
1.
go back to reference Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR: Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 1999, 398: 341-344.PubMedCrossRef Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR: Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 1999, 398: 341-344.PubMedCrossRef
Metadata
Title
CD30 involvement in self tolerance of T cells
Author
Sarah Parry
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-1999-66731

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine